Post-earnings recap
Reported
Tue, Nov 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kodiak Sciences reported a loss per share of $0.33, but did not disclose revenue figures. The stock fell by 6.10%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to navigate its clinical pipeline without specific targets.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to progressing their clinical programs.
Management did not provide specific guidance for future quarters.
The focus remains on advancing the clinical pipeline.